Cigna Healthcare and MD Anderson Madrid – Hospiten present the guide 'Cancer in the company II' Published on 28/02/2024 The document distinguishes four key moments in the approach to cancer in the company, pre-diagnosis (anticipation, early diagnosis and prevention), diagnosis (impact management), treatment (support) and return to work (readaptation).
The ‘healthcare limbo’ of sarcoma patients Published on 12/07/2023 The rare nature of this type of cancer has resulted in a scarcity of research and, as a consequence, less consistent diagnostic and treatment criteria, along with the difficulty of accessing specific drugs
Genetic study and analysis of family history play a key role in the early diagnosis of cancer Published on 31/01/2023 In the case of a suspected hereditary cancer, annual monitoring of the patient allows the tumor to be detected at an early stage, which means a better prognosis
A multidisciplinary approach is key to the treatment of the more than one hundred types of sarcomas we deal with Published on 01/03/2022 All medical specialties may be involved in this disease, among the most common are Traumatology, Medical Oncology, Radiotherapy Oncology, Anatomic and Molecular Pathology, Radiodiagnosis, Rehabilitation and Plastic Surgery.
Un 10% de los cánceres se puede prevenir gracias a los estudios genéticos Published on 18/01/2022 Los pacientes que hayan padecido más de un tipo de cáncer o aquellas personas cuya familia presente más casos de cáncer de lo estadísticamente razonable, son los principales candidatos para realizar un estudio genético
Llega el encuentro Mujerhoy Cancer Care 2021 sobre Salud, Cuidados y Prevención del Cáncer en la Mujer Published on 07/05/2021 El próximo 19 de mayo, de 16:00 a 18:00 horas, conéctate en directo a una nueva edición del evento sobre el cáncer en la mujer.
Patients with sarcoma 'play' their best or worst prognosis in the first operation Published on 10/02/2020 22% of people diagnosed with cancer in Spain have a rare tumour, according to data from the Spanish Orphan and Infrequent Tumours Group (GETHI). In these cases, as with other rare diseases, the main problems are delayed diagnosis, reduced availability of therapeutic options and, above all, the difficulty of finding professionals who are experts in a disease that only affects a small part of the population.
Up to 95% of tumours are not hereditary Published on 13/01/2020 According to estimates by the Spanish Cancer Registers Network (REDECAN), at the end of 2019 more than 275,000 cases of cancer were diagnosed in our country
MD Anderson Madrid – Hospiten and El Economista join Movember to offer health advice for men over 40 Published on 14/11/2019 This year the MD Anderson Cancer Center Madrid – Hospiten has again joined in with the Movember movement, an initiative now over ten years old that seeks to boost men’s healthcare during November.
Dr. Ricardo Cubedo, new head of Sarcomas and Hereditary Cancer at MD Anderson Cancer Center Madrid – Hospiten Published on 16/07/2019 Dr. Cubedo is a member of the Spanish Breast Cancer Research Group (GEICAM) and Sarcomas (GEIS), as well as a designated expert with the European Medicines Agency (EMA), among other leading positions